FDA Approves Biosimilar to Humira

Jun 30, 2017 | Kanaaz Pereira, Connect Moderator | @kanaazpereira | Comments (1)

The FDA recently approved a biosimilar (trade name, Amjevita) to Humira (adalimumab). A biosimilar is a biological product that is highly similar to the originator drug, and has no clinical differences in terms of safety and effectiveness. Dr. Edward Loftus , M.D., talks about the potential of this drug to offer patients with chronic inflammatory diseases such as Crohn's and ulcerative colitis an additional treatment option, and explains the issues surrounding it.

For more information about IBD, visit mayoclinic.org/IBD.

Dr. Loftus is a gastroenterologist at Mayo Clinic.

Interested in more newsfeed posts like this? Go to the Gastroenterology & GI Surgery blog.

Edward Loftus | @edwardvlo | Jul 3, 2018

Most of the information in this video is correct; however, the manufacturers of the biosimilar and the original drugs have agreed to hold off on bringing this biosimilar to market for several years. So, although it is technically approved by the FDA, it isn't commercially available at this time. - Ed Loftus, MD July 3, 2018